Amgen: Pipeline, Products, Performance, Potential

Table of Contents

Principal Operating Results

Breaking News

Latest Results

EXECUTIVE SUMMARY

• Introduction
  • Current Growth Drivers
  • Key Late-Stage Products
  • Key Early-Stage Products
• Financial Performance 2005
  • Sales and Market Position
  • Income
    • Sales, Costs and Operating Income, 2005
  • Expenditure
    • Capital Expenditure
    • R&D Expenditure
    • R&D Expenditure and Capital Expenditure
  • Divisional Performance
  • Geographic Performance
    • Sales By Geographical Area
    • Sales By Geographic Area, 2005
    • Long-Lived Assets By Geographical Area
    • Product Sales By Geographical Area
    • Product Sales By Geographical Area
    • Aranesp Sales By Geographic Area
    • Neulasta/Neupogen Sales By Geographic Area
    • Enbrel Sales By Geographic Area
• Company Strategy
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
  • Production
  • Employees
• Product / R&D Overview
  • Key Products
    • Recent Product Launches
    • Recent Product Approvals
  • R&D Strategy
    • Key R&D Projects
  • R&D Pipeline Overview
  • Discontinued R&D projects
    • LymphoCide
    • GDNF
    • Plenaxis
  • Sales Forecast
  • Sales of Major Products (2000A-2010E)
• Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

• Major Products, Therapeutic Areas and Sales
• Major Product Sales, 2005
• R&D Pipeline
• Haematology - Products
  • Major Launched Products
  • Aranesp/Nespo
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Safety Issues
    • Patents
    • Lawsuit
    • Competitor Products
    • Sales Forecast
  • Aranesp Sales (2000A-2010E)
    • Clinical Trial Results in Heart Failure
    • Clinical Trial Results in Myelodysplastic Syndromes
    • Clinical Trial Results in Chronic Kidney Disease
    • Clinical Trial Results - TREAT
  • Epogen
    • Sales
    • Key Markets/Indications/Formulations
    • Patents
    • Lawsuits
    • TKT/sanofi-aventis
    • Roche
    • Generic Competition
    • Competitor Products
    • Sales Forecast
  • Epogen Sales (2000A-2010E)
    • Clinical Trial Results
• Haematology - R&D
  • AMG 531
    • Clinical Trial Results
• Haematology - Summary
  • Growth Potential
  • Limiting Factors
• Immunology - Products
  • Major Launched Products
  • Neulasta
    • Sales
    • Key Markets/Indications/Formulations
    • Sales Forecast
  • Neulasta Sales (2000A-2010E)
    • Clinical Trial Results
  • Neupogen/Granulokine
    • Sales
    • Key Markets/Indications
    • Patents
    • Lawsuits
    • Genentech
    • Chugai
    • Generic Competition
    • Competitor Products
    • Sales Forecast
  • Neupogen Sales (2000A-2010E)
  • Infergen
    • Key Markets/Indications/Formulations
    • Further Development
    • Lawsuit
• Immunology - Summary
  • Growth Potential
  • Limiting Factors
• Inflammation - Products
  • Major Launched Products
  • Enbrel
    • Sales
    • Key Markets/Indications/Formulations
    • Patents
    • Lawsuit
    • Competitor Products
    • Sales Forecast
  • Enbrel Sales (2000A-2010E)
    • Clinical Trial Results
    • Clinical Trial Results in Rheumatoid Arthritis
    • Clinical Trial Results in Juvenile Rheumatoid Arthritis
  • Kineret
    • Key Markets/Indications/Formulations
    • Competitor Products
    • Clinical Trial Results
• Inflammation - R&D
  • AMG 108
  • AMG 623
  • AMG 714
  • Denosumab
    • Clinical Trial Results
• Inflammation - Summary
  • Growth Potential
  • Limiting Factors
• Oncology - Products
  • Kepivance
    • Further Development
    • Clinical Trial Results
  • Novantrone
    • Key Markets/Indications/Formulations
    • Safety Issues
• Oncology - R&D
  • AMG 102
  • AMG 386
  • AMG 479
  • AMG 655
  • AMG 706
  • AMG 951
  • Panitumumab
    • Clinical Trial Results
• Oncology - Summary
  • Growth Potential
  • Limiting Factors
• Metabolic Disorders - R&D
  • AMG 076
  • AMG 221
• Metabolic - Summary
• Neuroscience - R&D
  • AMG 403
  • AMG 517
• Neuroscience - Summary
• Other - Products
  • Sensipar/Mimpara
    • Key Markets/Indications
    • Further Development
• Other - R&D
  • AMG 009
  • AMG 317

APPENDIX 1 - FINANCIAL PERFORMANCE

• Full Year Results 2005
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&D Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

• Abgenix Inc
  • 26th July 2000
  • 28th November 2000
  • 9th January 2001
  • 10th July 2001
  • 14th October 2003
  • 13th August 2004
  • 13th January 2005
• Array BioPharma Inc
  • 3rd October 2000
  • 14th January 2002
• Biovitrum AB
  • 21st October 2003
  • 13th February 2006
• Boehringer Ingelheim Pharma KG
  • 5th November 1998
  • 27th June 2000 and 3rd June 2002
• Cambridge Antibody Technology Ltd (CAT)
  • 1st December 2000
  • 21st May 2001
  • 8th January 2002
  • 24th December 2003
• Celltech Group plc
  • 17th May 2002
• Eli Lilly
  • 16th December 1999
  • 7th November 2001
  • 12th November 2002
• Genmab A/S
  • 17th May 1999
  • 8th October 2001
  • 1st July 2003
  • 16th September 2003
• GlaxoSmithKline
  • 6th August 1998
• Human Genome Sciences Inc (HGS)
  • 9th January 2006
• Infinity Pharmaceuticals Incorporated
  • 8th January 2004
• InterMune Inc
  • 15th June 2001
  • 28th November 2005
• Isis Pharmaceuticals Inc
  • 13th December 2001
  • 3rd January 2002
  • 14th August 2002
  • 10th February 2003
• Johnson & Johnson
  • September 1985
• Kirin Brewery Co Ltd/ Kirin-Amgen
  • 1994
  • July 1996
• Medarex Inc
  • 12th January 1999
  • May 1999
  • 23rd September 1999
  • 4th November 2003
  • 29th November 2004
  • 24th February 2005
• NeoGenesis Pharmaceuticals Inc
  • 4th August 2003
• NPS Pharmaceuticals Inc
  • 18th March 1996
  • 8th March 2004
  • 9th August 2004
• Orion Corporation
  • 16th December 2003
• Regeneron Pharmaceuticals Inc
  • 31st August 1990
  • 21st September 1994
  • 16th April 1996
• Roche
  • Genentech agreement
  • 8th June 1999
  • 15th April 2002
  • 23rd June 2005
  • 26th January 2006
  • Roche agreement
  • 14th April 1997
  • 1st June 1999
  • May 2002
• SkyePharma Plc
  • 4th April 2000
• Wyeth
  • 25th September 1997
• ZymoGenetics Inc
  • 23rd January 2003
  • 20th May 2004
• Licensing
• Co-Promotion/Co-Marketing

APPENDIX 4 - INFRASTRUCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

• Subsidiaries
• Joint Ventures

APPENDIX 6 - PRODUCT INDEX